A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening

Vox Sang. 2013 Nov;105(4):290-8. doi: 10.1111/vox.12060. Epub 2013 Jun 27.

Abstract

Background and objectives: This report describes a method for estimating the risk of transfusion-transmitted HBV infection attributable to blood components from donors with occult hepatitis B virus infection (OBI) applicable where universal anti-HBc screening is not performed.

Materials and methods: In the context of parallel HBsAg and individual donation HBV DNA testing, we developed a mathematical function p(OBI) to estimate the probability of failing to detect [p(NAT nondetection)] a potentially infectious [p(transmission)] donation from a donor with OBI.

Results: Among 1 312 451 donations tested for HBsAg and HBV DNA, 29 (from 17 anti-HBc reactive donors classified as OBI) were individual donation NAT negative, giving a p(NAT nondetection) of 2·2096 (95 CI: 1·538-3·173) × 10(-5) . To date, lookback on OBI donors has identified 35 (8·2%) recipients with evidence of current or past HBV infection among 427 tested recipients. After correcting for the background anti-HBc rate in recipients, this results in a p(transmission) of 0·0384 (0·0167-0·0601). The product, pOBI is 1 in 981 920 (95% CI: 437 181-3 223 701). When this is summed with the WP risk for the 2011-2012 period, the overall HBV residual risk estimate is 1 in 538 224 (95% CI: 209 732-1 552 443).

Conclusion: We estimate the OBI residual risk in Australia is approximately 1 in 982 000 per unit transfused, and this risk represents 55% of the total HBV residual risk and is declining as consequence of ID-NAT identifying repeat donors with OBI.

Keywords: NAT testing; blood donation testing; residual risk estimation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Australia
  • Blood Donors*
  • DNA, Viral / blood
  • Hematologic Tests / methods
  • Hepatitis B / prevention & control
  • Hepatitis B / transmission*
  • Hepatitis B / virology
  • Hepatitis B Antibodies / blood
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B virus / genetics
  • Hepatitis B virus / immunology
  • Hepatitis B virus / isolation & purification*
  • Humans
  • Risk
  • Transfusion Reaction*

Substances

  • DNA, Viral
  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens